{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T04:22:05Z","timestamp":1776572525412,"version":"3.51.2"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:00:00Z","timestamp":1640044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100006304","name":"Aalborg University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006304","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>The aim of this study was to evaluate the risk of stroke and bleeding among patients with atrial fibrillation (AF) treated with direct oral anticoagulants (DOACs) despite anaemia at treatment initiation time.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>All Danish patients (N = 41\u00a0321) diagnosed with incident AF, having a baseline haemoglobin (Hb), and subsequently initiated DOAC therapy between 2012 and 2019 were identified through administrative registry databases. Patients with anaemia were subdivided according to the World Health Organization classification of anaemia and evaluated regarding risk of stroke and composite bleeding endpoint [hospitalization due to urogenital, gastrointestinal (GI), or intracranial bleeding or epistaxis]. Standardized absolute 1-year risks of stroke and composite bleeding endpoint were calculated using multivariable Cox regression analyses. The standardized absolute 1-year risk difference for composite bleeding increased by 0.96% [95% confidence interval (CI) 0.38\u20131.54] for patients with moderate\/severe anaemia compared with patients with no anaemia. This risk was mainly driven by an increase in standardized absolute 1-year risk for serious GI bleeding, which increased by 0.41% (95% CI 0.19\u20130.63). No significant difference in standardized absolute 1-year bleeding risk was observed among patients with mild anaemia compared with patients with no anaemia 0.36% (95% CI \u22120.10 to 0.82). No significant difference in standardized absolute 1-year risk of stroke was observed among patients with mild anaemia, \u22120.16% (95% CI \u22120.13 to 0.15), and moderate\/severe anaemia, \u22120.47% (95% CI \u22120.16 to 0.19), compared with patients with no anaemia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>For AF patients receiving DOACs, moderate\/severe anaemia is a risk factor for serious GI bleeding, while stroke risk is the same regardless of whether anaemia was present at baseline or not.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjqcco\/qcab095","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T20:24:44Z","timestamp":1639513484000},"page":"840-851","source":"Crossref","is-referenced-by-count":9,"title":["Safety and efficacy of direct oral anticoagulants in patients with anaemia and atrial fibrillation: an observational nationwide Danish cohort study"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9118-206X","authenticated-orcid":false,"given":"Nour","family":"Al-Hussainy","sequence":"first","affiliation":[{"name":"Department of Medicine, Slagelse Hospital , Ingemannsvej 30, 4200 Slagelse, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristian Hay","family":"Kragholm","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aalborg University Hospital , Aalborg, Denmark"},{"name":"Unit of Clinical Biostatistics and Epidemiology, Aalborg University Hospital , Aalborg, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00f8ren","family":"Lundbye-Christensen","sequence":"additional","affiliation":[{"name":"Unit of Clinical Biostatistics and Epidemiology, Aalborg University Hospital , Aalborg, Denmark"},{"name":"Department of Clinical Medicine, Aalborg University , Aalborg, Denmark"},{"name":"AF Study Group, Aalborg University Hospital , Aalborg, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Torp-Pedersen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, North Zealand Hospital , Hiller\u00f8d, Denmark"},{"name":"Department of Cardiology, Aalborg University Hospital , Aalborg, Denmark"},{"name":"Department of Public Health, University of Copenhagen , Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manan","family":"Pareek","sequence":"additional","affiliation":[{"name":"Department of Cardiology, North Zealand Hospital , Hiller\u00f8d, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susette Krohn","family":"Therkelsen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Slagelse Hospital , Ingemannsvej 30, 4200 Slagelse, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y H","family":"Lip","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Aalborg University , Aalborg, Denmark"},{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital , Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Riahi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aalborg University Hospital , Aalborg, Denmark"},{"name":"Department of Clinical Medicine, Aalborg University , Aalborg, Denmark"},{"name":"AF Study Group, Aalborg University Hospital , Aalborg, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,12,21]]},"reference":[{"key":"2022111711511727200_bib1","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrcardio.2017.153","article-title":"The ABC pathway: an integrated approach to improve AF management","volume":"14","author":"Lip","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"2022111711511727200_bib2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2022111711511727200_bib3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/2042098617744926","article-title":"Contemporary utilization of antithrombotic therapy for stroke prevention in patients with atrial fibrillation: an audit in an Australian hospital setting","volume":"9","author":"Pandya","year":"2018","journal-title":"Ther Adv Drug Saf"},{"key":"2022111711511727200_bib4","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"2022111711511727200_bib5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0002-9343(98)00198-3","article-title":"Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin","volume":"105","author":"Beyth","year":"1998","journal-title":"Am J Med"},{"key":"2022111711511727200_bib6","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1378\/chest.130.5.1390","article-title":"Development of a contemporary bleeding risk model for elderly warfarin recipients","volume":"130","author":"Shireman","year":"2006","journal-title":"Chest"},{"key":"2022111711511727200_bib7","doi-asserted-by":"crossref","first-page":"e012029","DOI":"10.1161\/JAHA.119.012029","article-title":"Safety and effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation and anemia: a retrospective cohort study","volume":"8","author":"Wang","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2022111711511727200_bib8","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","article-title":"2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhyt","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"key":"2022111711511727200_bib9","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"2022111711511727200_bib10","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"2022111711511727200_bib11","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"2022111711511727200_bib12","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Aristotle committees and investigators. Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"2022111711511727200_bib13","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"2022111711511727200_bib14","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s11239-018-1698-y","article-title":"Warfarin for prevention of thromboembolism in atrial fibrillation: comparison of patient characteristics and outcomes of the \u2018Real-World\u2019 Michigan Anticoagulation Quality Improvement Initiative (MAQI2) registry to the RE-LY, ROCKET-AF, and ARISTOTLE trial","volume":"46","author":"Hughey","year":"2018","journal-title":"J Thromb Thrombolysis"},{"key":"2022111711511727200_bib15","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/bcpt.13024","article-title":"Use of non-vitamin K antagonist oral anticoagulants 2008\u20132016: a Danish nationwide cohort study","volume":"123","author":"Haastrup","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2022111711511727200_bib16","first-page":"91","article-title":"Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin*","volume":"105","author":"Beyth","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"2022111711511727200_bib17","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1111\/bcp.13299","article-title":"Trends in the prescription of novel oral anticoagulants in UK primary care","volume":"83","author":"Loo","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"2022111711511727200_bib18","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/1403494811401482","article-title":"The Danish national patient register","volume":"39","author":"Lynge","year":"2011","journal-title":"Scand J Public Health"},{"key":"2022111711511727200_bib19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/1403494810394717","article-title":"The Danish national prescription registry","volume":"39","author":"Wallach Kildemoes","year":"2011","journal-title":"Scand J Public Health"},{"key":"2022111711511727200_bib20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1403494810387965","article-title":"The Danish civil registration system","volume":"39","author":"Pedersen","year":"2011","journal-title":"Scand J Public Health"},{"key":"2022111711511727200_bib21","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/CLEP.S17901","article-title":"Existing data sources for clinical epidemiology: the clinical laboratory information system (LABKA) research database at Aarhus University, Denmark","volume":"3","author":"Grann","year":"2011","journal-title":"Clin Epidemiol"},{"key":"2022111711511727200_bib22","doi-asserted-by":"crossref","first-page":"d124","DOI":"10.1136\/bmj.d124","article-title":"Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study","volume":"342","author":"Olesen","year":"2011","journal-title":"BMJ"},{"key":"2022111711511727200_bib23","first-page":"1","author":"","year":"2011","journal-title":"Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity"},{"key":"2022111711511727200_bib24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/0962280209105020","article-title":"Pseudo-observations in survival analysis","volume":"19","author":"Perme","year":"2010","journal-title":"Stat Methods Med Res London"},{"key":"2022111711511727200_bib25","article-title":"Medical risk prediction models: with ties to machine learning (1st ed.)","author":"Gerds","year":"2021"},{"key":"2022111711511727200_bib26","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","article-title":"Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study","volume":"33","author":"Friberg","year":"2012","journal-title":"Eur Heart J"},{"key":"2022111711511727200_bib27","first-page":"78","article-title":"Anemia: an independent predictor of adverse outcomes in older patients with atrial fibrillation","volume":"8","author":"Ali","year":"2016","journal-title":"J Atr Fibrillation"},{"key":"2022111711511727200_bib28","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1093\/eurheartj\/ehz155","article-title":"Oral anticoagulation among atrial fibrillation patients with anaemia: an observational cohort study","volume":"40","author":"Bonde","year":"2019","journal-title":"Eur Heart J"},{"key":"2022111711511727200_bib29","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ahj.2016.12.008","article-title":"Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial","volume":"185","author":"Westenbrink","year":"2017","journal-title":"Am Heart J"},{"key":"2022111711511727200_bib30","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jacc.2013.11.013","article-title":"Factors associated with major bleeding events: insights from the ROCKET AF trial (Rivaroxaban Once-Daily Oral Direct Factor XA Inhibition Compared with Vitamin k Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)","volume":"63","author":"Goodman","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2022111711511727200_bib31","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/jth.12874","article-title":"Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE-LY trial","volume":"13","author":"Westenbrink","year":"2015","journal-title":"J Thromb Haemost"},{"key":"2022111711511727200_bib32","first-page":"70","article-title":"Frequency and predictors of bleeding complications associated with anti-coagulant therapy using dabigatran in Japanese patients with atrial fibrillation","volume":"4","author":"Katoh","year":"2014","journal-title":"Am J Cardiovasc Dis"},{"key":"2022111711511727200_bib33","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1136\/gut.36.4.483","article-title":"Acute gastrointestinal haemorrhage in patients treated with anticoagulant drugs","volume":"36","author":"Choudari","year":"1995","journal-title":"Gut"},{"key":"2022111711511727200_bib34","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(89)80689-8","article-title":"Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy","volume":"87","author":"Landefeld","year":"1989","journal-title":"Am J Med"},{"key":"2022111711511727200_bib35","doi-asserted-by":"crossref","first-page":"511","DOI":"10.7326\/0003-4819-118-7-199304010-00005","article-title":"Risk factors for complications of chronic anticoagulation: a multicenter study","volume":"118","author":"Fihn","year":"1993","journal-title":"Ann Intern Med"},{"key":"2022111711511727200_bib36","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"2022111711511727200_bib37","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/j.gastro.2013.02.041","article-title":"New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis","volume":"145","author":"Holster","year":"2013","journal-title":"Gastroenterology"},{"key":"2022111711511727200_bib38","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/apt.13412","article-title":"Systematic review with meta-analysis: the risk of major gastrointestinal bleeding with non-vitamin K antagonist oral anticoagulants","volume":"42","author":"Caldeira","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2022111711511727200_bib39","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.amjcard.2012.03.049","article-title":"Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation","volume":"110","author":"Miller","year":"2012","journal-title":"Am J Cardiol"},{"key":"2022111711511727200_bib40","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/bcp.12911","article-title":"The association between non-vitamin K antagonist oral anticoagulants and gastrointestinal bleeding: a meta-analysis of observational studies","volume":"82","author":"He","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"2022111711511727200_bib41","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/europace\/euv119","article-title":"Risk of gastrointestinal adverse effects of dabigatran compared with warfarin among patients with atrial fibrillation\u202f: a nationwide cohort study","volume":"17","author":"Staerk","year":"2015","journal-title":"Europace"},{"key":"2022111711511727200_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2019.10.013","article-title":"Gastrointestinal bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial","volume":"221","author":"Garcia","year":"2020","journal-title":"Am Heart J"},{"key":"2022111711511727200_bib43","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/j.jacc.2015.09.024","article-title":"Gastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin: ROCKET AF trial","volume":"66","author":"Sherwood","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2022111711511727200_bib44","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.amjcard.2020.08.009","article-title":"Cardiovascular events and mortality in patients with atrial fibrillation and anemia (from the Fushimi AF Registry)","volume":"134","author":"An","year":"2020","journal-title":"Am J Cardiol"},{"key":"2022111711511727200_bib45","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41569-020-00459-3","article-title":"Stroke prevention strategies in high-risk patients with atrial fibrillation","volume":"18","author":"Kotalczyk","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"2022111711511727200_bib46","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.amjmed.2005.12.027","article-title":"Trend in mortality after stroke with atrial fibrillation","volume":"120","author":"Frost","year":"2007","journal-title":"Am J Med"},{"key":"2022111711511727200_bib47","doi-asserted-by":"crossref","first-page":"e012832","DOI":"10.1136\/bmjopen-2016-012832","article-title":"Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study","volume":"6","author":"Sundb\u00f8ll","year":"2016","journal-title":"BMJ Open"},{"key":"2022111711511727200_bib48","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.thromres.2015.04.004","article-title":"Safety of the direct-acting anticoagulants in patients with atrial fibrillation: a meta-analysis","volume":"135","author":"Rong","year":"2015","journal-title":"Thromb Res"}],"container-title":["European Heart Journal - Quality of Care and Clinical Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjqcco\/advance-article-pdf\/doi\/10.1093\/ehjqcco\/qcab095\/42902680\/qcab095.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article-pdf\/8\/8\/840\/47099666\/qcab095.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article-pdf\/8\/8\/840\/47099666\/qcab095.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T11:51:58Z","timestamp":1668685918000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article\/8\/8\/840\/6472235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,21]]},"references-count":48,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,12,21]]},"published-print":{"date-parts":[[2022,11,17]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjqcco\/qcab095","relation":{},"ISSN":["2058-5225","2058-1742"],"issn-type":[{"value":"2058-5225","type":"print"},{"value":"2058-1742","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12]]},"published":{"date-parts":[[2021,12,21]]}}}